CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation

Launched by ST. JUDE CHILDREN'S RESEARCH HOSPITAL · Jul 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the long-term health of people who were treated for medulloblastoma, a type of brain tumor, with radiation therapy to the brain and spine. The goal is to understand the lasting effects of treatment, such as problems with thinking, hearing loss, heart and lung health, hormone issues, bone and muscle problems, and fertility concerns. This information will help doctors decide the best ways to check on survivors’ health in the future.

People who might be eligible for this study include those who were diagnosed with any type of medulloblastoma between the ages of 3 and 22, or those aged 22 to 44 with a specific subtype called sonic hedgehog (SHH). Participants must have received radiation treatment following a certain plan and be at least five years past the start of their radiation without the cancer coming back. If you join, you can choose to take part in all or some of the tests and assessments the study offers. It’s important to know that the study is not yet recruiting participants, and anyone interested will need to give informed consent (or have a guardian do so) before joining.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of any subtype of medulloblastoma between the ages of 3 to 22 years or between the ages of 22 to 44 years with the sonic hedgehog (SHH) subtype of medulloblastoma
• • Radiotherapy on or according to the SJMB12 protocol
• • 5 or more years since the initiation of radiation therapy and who did not have evidence of disease progression
• • Provision of informed consent by participant/guardian or legal representative; Assent by minor participant
• • Participants may choose to complete all or a subset of the proposed assessments; refusal to participate in some aspects of the study will not preclude participant inclusion
• • Participants must also complete enrollment on SJLIFE
• Exclusion Criteria:
• • Participants or their legal guardian/representative are unwilling or unable to provide written informed consent.
• • Participants who had relapsed or refractory disease during or following completion of treatment for medulloblastoma